PREPAIR-VAC PREParedness using Artificial Intelligence for Rapid VACcine design
- Coordinator
- European Vaccine Initiative eV, Germany
- Runs
- 1 September 2026 to 31 August 2030
- Status
- Running
- EU funding
- €6.6m
- Total cost
- €6.6m
- Partners
- 9 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101289538
What the project is doing
In the project's own words, from its summary on CORDIS.
Zoonotic diseases are the cause of >70% of emerging infectious diseases. In PREPAIR-VAC, we use Influenza, specifically H1N1 as a model disease. Vaccination is considered the most effective public health measure to prevent the impact of any viral threats, including Influenza. Current vaccine design approaches are reactive by nature and will require to know the circulating strain before designing the vaccine. As a result, viruses can spread widely before the vaccine is made available, making vaccine design and production major bottlenecks in rapid outbreak response.
The main objective of the project is to establish and validate a rapid, scalable, and modular AI-driven pipeline for vaccine development that addresses every critical component of the pipeline: prediction of the evolution of pathogens, antigen selection and vaccine design and manufacturability. To achieve this ambitious goal, we have designed a comprehensive methodology that couples the development and validation of AI toolkits with efficient technologies for vaccine manufacturing and formulation with potential for rapid upscale and efficient roll out.
Furthermore, we will also address the ethical, legal and social dimensions of potential AI-driven vaccines through stakeholder engagement activities to evaluate barriers to their acceptance and deployment. Addressing societal concerns is essential to ensure the development of trustworthy, ethical and unbiased AI-driven solutions and the successful uptake of novel vaccine technologies. AI-driven solutions can become the key to shortening the path from an outbreak to available vaccine doses - strengthening Europe’s capacity to react to pandemics by increasing resilience, autonomy, and preparedness.
PREPAIR-VAC represents a decisive step forward in this direction by offering a scalable AI-driven pipeline for vaccine development, readily adaptable to respond to other infectious diseases.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| European Vaccine Initiative eV | Heidelberg | Germany | Coordinator |
| Medizinische Hochschule Hannover | Hannover | Germany | Third party |
| Nec Bio Therapeutics GmbH | Mannheim | Germany | Third party |
| Niedersachsisches Landesgesundheitsamt | Hannover | Germany | Participant |
| Croda Denmark A/S | Frederikssund | Denmark | Participant |
| Nevezyne | Saint-Brieuc | France | Participant |
| Universite Jean Monnet | Saint-Etienne | France | Participant |
| Nec Oncoimmunity AS | Oslo | Norway | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI